Study Finds Radium-223 Effective in Prostate Cancer Treatment Independently of Docetaxel Use

Study Finds Radium-223 Effective in Prostate Cancer Treatment Independently of Docetaxel Use
A recent study titled “Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial”, published in The Lancet Oncology journal, has concluded that radium-223 dichloride (Xofigo), a radiopharmaceutical drug for prostate cancer treatment, is effective independently of previous chemotherapy treatment. After promising results from the ALSYMCA trial, Ra223 was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Now, the same researchers who conducted the previous trial designed a prespecified subgroup analysis from ALSYMPCA in order to understand the effect of previous docetaxel use on the efficacy and safety of radium-223. Robert B. Den, MD, and W. Kevin Kelly, DO, from the Departments of Radiation and Medical Oncology, at Thomas Jefferson University in Philadelphia, wrote an accompanying comment in the same journal edition, where they stated that "men who have received previous docetaxel chemotherapy can be given radium-223 safely and its efficacy will be similar to patients who have not received previous docetaxel treatment. The oncology community needs to proceed cautiously, since the ALSYMPCA trial was not able to identify the optimum sequence of administration of docetaxel and radium-233. Additionally, the trial was designed before the approval of enzalutamide and abiraterone acetate, so the clinical benefit of concomitant or sequential use of radium-223 with these drugs is unknown. Perhaps most intriguing would be the opportunity to integrate immunotherapy." In this phase 3, randomised, double-blind ALSYMPCA trial, pa
Subscribe or to access all post and page content.